Completed PHASE2 INTERVENTIONAL NCT00050882

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis

Sponsor: Chugai Pharma USA

Conditions Gastroparesis

Interventions GM-611

Updated 6 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00050882, this PHASE2 trial focuses on Gastroparesis and remains completed. Sponsored by Chugai Pharma USA, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chugai Pharma USA

Data source: Chugai Pharma USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amarillo, United States , Anaheim, United States , Arvada, United States , Atlanta, United States , Binghamton, United States , Boise, United States , Bradenton, United States , Charleston, United States , Charlotte, United States and 50 more locations